Cited by 273Bacterial Cancer TherapyCAR-T cell therapy researchImmunotherapy and Immune Responses

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Probiotic-guided CAR-T cells for solid tumor targeting

Open access

Vincent, Rosa L., Gurbatri, Candice R., Li, Fangda, Vardoshvili, Ana, Coker, Courtney, Im, Jongwon, Ballister, Edward R., Rouanne, Mathieu, Savage, Thomas, de los Santos-Alexis, Kenia, Redenti, Andrew, Brockmann, Leonie, Komaranchath, Meghna, Arpaia, Nicholas, Danino, Tal·2023·Science

DOI 10.1126/science.add7034PMC PMC10915968

Open this paper in CoChat — free account Open PDF

Abstract

A major challenge facing tumor-antigen targeting therapies such as chimeric antigen receptor (CAR)–T cells is the identification of suitable targets that are specifically and uniformly expressed on heterogeneous solid tumors. By contrast, certain species of bacteria selectively colonize immune-privileged tumor cores and can be engineered as antigen-independent platforms for therapeutic delivery. To bridge these approaches, we developed a platform of probiotic-guided CAR-T cells (ProCARs), in which tumor-colonizing probiotics release synthetic targets that label tumor tissue for CAR-mediated lysis in situ. This system demonstrated CAR-T cell activation and antigen-agnostic cell lysis that was safe and effective in multiple xenograft and syngeneic models of human and mouse cancers. We further engineered multifunctional probiotics that co-release chemokines to enhance CAR-T cell recruitment and therapeutic response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.add7034

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,847
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,233
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,103
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833

Show all 65 references

Sorted by citations

Cancer treatments: Past, present, and future
Sonkin, D., Thomas, A., & Teicher, B. A. (2024) · Cancer Genetics · doi:10.1016/j.cancergen.2024.06.002 · Cited by 597
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 122
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization
Chang, Z., Guo, X., Li, X., Wang, Y., Zang, Z., Pei, S., Lu, W., Li, Y., Huang, J., Xiao, Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.02.002 · Cited by 119
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses
Yang, S., Sheffer, M., Kaplan, I. E., Wang, Z., Tarannum, M., Dinh, K., Abdulhamid, Y., Bobilev, E., Shapiro, R., Porter, R., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02418-6 · Cited by 66
Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms
Li, F., Yang, Z., Savage, T. M., Vincent, R. L., Santos, K. D. L., Ahn, A., Rouanne, M., Mariuzza, D. L., Danino, T., & Arpaia, N. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn9879 · Cited by 59
Self-citation
Tannic acid-based metal-phenolic networks as a versatile platform to mediate cell therapy
Luo, H., Xie, J., Su, X., Wang, P., Chen, H., Kuang, X., & Liu, J. (2024) · Science China Materials · doi:10.1007/s40843-024-3139-3 · Cited by 59
Intratumoral Microbiota as a Target for Advanced Cancer Therapeutics
Peng, F., Hu, M., Su, Z., Hu, L., Guo, L., & Yang, K. (2024) · Advanced Materials · doi:10.1002/adma.202405331 · Cited by 57
Innovative Applications of Bacteria and Their Derivatives in Targeted Tumor Therapy
Zhu, D., Pan, W. X., Li, H., Hua, J., Zhang, C., & Zhao, K. (2025) · ACS Nano · doi:10.1021/acsnano.4c15237 · Cited by 56
Microbe-material hybrids for therapeutic applications
Chen, M., Xia, L., Wu, C., Wang, Z., Ding, L. S., Xie, Y., Feng, W., & Chen, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00655g · Cited by 56
SynNotch CAR-T cell, when synthetic biology and immunology meet again
Shirzadian, M., Moori, S., Rabbani, R., & Rahbarizadeh, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545270 · Cited by 55
The tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 57
Nano/genetically engineered cells for immunotherapy
Shen, J., Zhou, Y., & Yin, L. (2024) · BMEMat · doi:10.1002/bmm2.12112 · Cited by 50
Engineered bacteria launch and control an oncolytic virus
Singer, Z. S., Pabón, J., Huang, H., Sun, W. Y., Luo, H., Grant, K. R., Obi, I., Coker, C., Rice, C. M., & Danino, T. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01476-8 · Cited by 51
Self-citation
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors
Zhu, C., Liu, C., Wu, Q., Sheng, T., Zhou, R., Ren, E., Zhang, R., Zhao, Z., Shi, J., Shen, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02028-3 · Cited by 51
Synthetic Biology‐Based Engineering Cells for Drug Delivery
Yi, W., Hu, S., Qian, X., Yan, W., & Li, Y. (2025) · Exploration · doi:10.1002/exp.20240095 · Cited by 49
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
Zhang, T., Tai, Z., Miao, F., Zhang, X., Li, J., Zhu, Q., Wei, H., & Chen, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.033 · Cited by 47
Engineering bacteria for cancer immunotherapy
Zalatan, J. G., Petrini, L. F. T., & Geiger, R. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103061 · Cited by 42
Engineered bacteria in tumor immunotherapy
Chen, H., Zhu, Y., Zhang, C., Hu, L. T., & Yang, K. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216817 · Cited by 40
Amplifying Synergistic Effects of Cuproptosis and Bacterial Membrane Vesicles‐Mediated Photothermal Therapy by Multifunctional Nano‐Biohybrid for Anti‐Tumor Immunotherapy
Niu, M., Li, Q., Huang, Q., Qin, Y., Meng, D., Liang, J., & Zhang, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202413255 · Cited by 40
Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
Zhang, B., Wu, J., Jiang, H., & Zhou, M. (2025) · Cells · doi:10.3390/cells14050320 · Cited by 39
Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Zhu, C., Wu, Q., Sheng, T., Shi, J., Shen, X., Yu, J., Du, Y., Sun, J., Liang, T., He, K., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.002 · Cited by 39
The emerging landscape of engineered bacteria cancer therapies
Ballister, E. R., Michels, A., Vincent, R. L., Kreindler, L., Chowdhury, S., Upadhaya, S., Saez-Ibañez, A. R., Tu, T., Gottweis, J., & Danino, T. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02623-x · Cited by 34
Self-citation
Review of the Potential of Probiotics in Disease Treatment: Mechanisms, Engineering, and Applications
Liu, M., Chen, J., Dharmasiddhi, I. P. W., Chen, S., Liu, Y., & Liu, H. (2024) · Processes · doi:10.3390/pr12020316 · Cited by 35
Engineered radiation-sensitive probiotic for synergistic tumor cell cycle blockade and immunomodulation to potentiate radio-immunotherapy in pancreatic cancer
Yao, W.-Q., Zhang, S., Hu, X., He, L., Meng, R., Lin, Y.-T., Chen, W.-H., & Zhang, X.-Z. (2025) · Materials Today · doi:10.1016/j.mattod.2025.03.018 · Cited by 34
Bacterial live therapeutics for human diseases
Frutos-Grilo, E., Ana, Y., Miguel, J. G.-D., Cardona-I-Collado, M., Rodríguez-Arce, I., & Serrano, L. G. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00067-0 · Cited by 36
The Pentose Phosphate Pathway: From Mechanisms to Implications for Gastrointestinal Cancers
Qiao, J., Yu, Z., Zhou, H., Wang, W., Wu, H., & Ye, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020610 · Cited by 32
Overcoming immunotherapy resistance in colorectal cancer through nano-selenium probiotic complexes and IL-32 modulation
Li, S., Liu, T., Li, C., Zhang, Z., Zhang, J., & Sun, D. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123233 · Cited by 33
Designing live bacterial therapeutics for cancer
Lee, J., McClure, S., Weichselbaum, R. R., & Mimee, M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115579 · Cited by 31
Engineering Cells for Cancer Therapy
Liu, P., & Hu, Q. (2024) · Accounts of Chemical Research · doi:10.1021/acs.accounts.4c00293 · Cited by 29
Emerging nanomedicines for macrophage-mediated cancer therapy
Shi, X., Rizvi, S. F. A., Yang, Y., & Liu, G. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123028 · Cited by 32
Utilizing Engineered Bacteria as “Cell Factories” In Vivo for Intracellular RNA-Loaded Outer Membrane Vesicles’ Self-Assembly in Tumor Treatment
Sun, D., Li, Y., Yin, X., Fan, Y., Liu, J., Wang, Y., Liu, X., Bai, G., Li, K., Shi, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c11412 · Cited by 29
Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy
Xu, Y., Zhang, X., Han, X., Huang, H., Meng, C., Yang, Y., Sheng, T., Ren, E., Shi, J., He, K., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.015 · Cited by 28
Programmable Bacteria with Dynamic Virulence Modulation System for Precision Antitumor Immunity
Wu, L., Li, L., Qiao, L., Li, C., Zhang, S., Yin, X., Du, Z., Sun, Y., Qiu, J., Chang, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202404069 · Cited by 24
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
Li, X., Chen, T., Li, X., Zhang, H., Li, Y., Zhang, S., Luo, S., & Zheng, T. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00564-w · Cited by 28
Screening Natural Cholesterol Analogs to Assemble Self‐Adjuvant Lipid Nanoparticles for Antigens Tagging Guided Therapeutic Tumor Vaccine
Liang, S., Gao, S., Fu, S., Yuan, S., Liu, J., Liang, M., Han, L., Zhang, Z., Liu, Y., & Zhang, N. (2025) · Advanced Materials · doi:10.1002/adma.202419182 · Cited by 26
Self‐Adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery
Zou, Z., Wang, X., Shi, X., Sun, S., Mi, J., Zhang, X. P., Yin, B., Zhou, Y. Q., & Ye, B. (2025) · Advanced Science · doi:10.1002/advs.202406486 · Cited by 28
RETRACTED ARTICLE: Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy
Li, X., Li, X., Shi, J., Li, Y., Zhang, H., Chen, T., Pang, H., Zhang, S., Luo, S., Liu, F., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01575-6 · Cited by 28
Retracted
Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells
Ahmed, E. N., Cutmore, L. C., & Marshall, J. F. (2024) · Cancers · doi:10.3390/cancers16183186 · Cited by 32
Natural Enzyme‐Loaded Polymeric Stealth Coating‐Armed Engineered Probiotics by Disrupting Tumor Lactate Homeostasis to Synergistic Metabolism‐Immuno‐Enzyme Dynamic Therapy
Mao, L., Xarpidin, B., Shi, R., Lin, Y.-T., Hu, H., Wu, C., Luo, Z., & Wu, Y. (2025) · Advanced Science · doi:10.1002/advs.202417172 · Cited by 24
The new microbiome on the block: challenges and opportunities of using human tumor sequencing data to study microbes
Li, Y., Ma, A., Johnson, W. E., Eng, C., De, S., Jiang, S., Li, Z., Spakowicz, D. J., & Ma, Q. (2025) · Nature Methods · doi:10.1038/s41592-025-02807-y · Cited by 25
Surface-functionalized bacteria: Frontier explorations in next-generation live biotherapeutics
Jiang, J.-N., Kong, F., Lei, Q., & Zhang, X. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123029 · Cited by 24
Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer
Chen, Q., Sun, J., Ling, S., Yang, H., Li, T., Yang, X., Li, M., Du, M., Zhang, Y., Li, C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c17899 · Cited by 23
Microrobotic Swarms for Cancer Therapy
Xie, L., Liu, J., Yang, Z., Chen, H., Wang, Y., Du, X., Fu, Y., Song, P., & Yu, J. (2025) · Research · doi:10.34133/research.0686 · Cited by 22
Current advances in bacteria‐based cancer immunotherapy
Guo, C., Liu, J., & Zhang, Y. (2023) · European Journal of Immunology · doi:10.1002/eji.202350778 · Cited by 21
Gut microbiota and immunosenescence in cancer
Xu, Y., He, C., Xi, Y., Zhang, Y., & Bai, Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.004 · Cited by 23
Empowering probiotics with high xanthine transport for effective hyperuricemia management
Zou, Z., Li, J.-L., Zhang, Y., Zhou, Y. Q., & Ye, B. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2399213 · Cited by 21
Living therapeutics of nonpathogenic bacteria as biosynthesis factory and active carriers for enhancing tumor-targeted therapy
Dong, M., Yang, X., Zhang, W., Qiu, Y., Song, P., Liu, H., Yang, X., Yang, X., & Wang, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-61675-4 · Cited by 22
Recent advances of engineered probiotics for therapeutic applications
Zhang, L., Chen, N., Chen, H., Tang, C., Wang, J., Wang, Y., Zhang, Y., Guo, H., & Yuan, J. (2025) · BioDesign Research · doi:10.1016/j.bidere.2025.100039 · Cited by 24
Programmable probiotics as next-generation living therapeutics: bridging synthetic biology and precision medicine
Li, N., Yin, L., Wang, J., Zhang, J., & Tong, Y. (2025) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2025.103375 · Cited by 22
The role of gut microbiome in aging-associated diseases: where do we stand now and how technology will transform the future
Aldriwesh, M. G., Alotibi, R. S., Alqurainy, N., Alrabiah, S., Arafah, A. M., Alghoribi, M. F., & Ajina, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2607076 · Cited by 21
Chemically modified and inactivated bacteria enable intra-biofilm drug delivery and long-term immunity against implant infections
Yang, C., Saiding, Q., Chen, W., An, S., Zhao, S., Khan, M. M., Kong, N., Ge, M., Shi, J., Lin, H., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01600-8 · Cited by 22
Paving the way for bacteria-based drug delivery: biohybrid microrobots emerging from microrobotics and synthetic biology
Totter, E., von Einsiedel, E., Regazzoni, L., & Schuerle, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115577 · Cited by 20
Engineered bacteria for cancer therapy: Advancements, challenges, and future directions
Wang, M.-G., Liu, M., Wang, D., Yang, D., Zeng, Y., Lan, Y., & Wang, Q. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003807 · Cited by 19
Programmable Smart CAR-T design: A new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence
Wen, P., Ai, Q., Fan, X., Gu, Z., 陈波, & Qian, H. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218257 · Cited by 20
Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery
Zhang, X., Yue, L., Cao, L., Liu, K., Yang, S., Liang, S., Liu, L., Zhao, C., Wu, D., Wang, Z., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.07.042 · Cited by 21
Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens
Gamboa, L., Zamat, A. H., Thiveaud, C., Lee, H. J., Kulaksizoglu, E., Zha, Z., Campbell, N., Chan, C. S., Fábrega, S., Oliver, S. A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00968-5 · Cited by 25
Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives
Niu, L., Deng, Z., Jin, Y., Guan, N., & Ye, H. (2025) · Protein & Cell · doi:10.1093/procel/pwaf085 · Cited by 19
Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits
Wang, Y., Xiao, S., Yu, W., Han, B. R., & Guo, G. F. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01766-3 · Cited by 20
Physiochemically and Genetically Engineered Bacteria: Instructive Design Principles and Diverse Applications
Lin, X., Jiao, R., Cui, H., Yan, X., & Zhang, K. (2024) · Advanced Science · doi:10.1002/advs.202403156 · Cited by 16
Nanobiohybrid Oncolytic Bacteria with Optimized Intratumoral Distribution for Combined Sono–Photodynamic/Immunotherapy
Zhang, X., Zang, Z., Liang, Z., Xu, X., Zheng, J., Liang, N., Shabiti, S., Wang, Z., Yu, S., Wang, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16740 · Cited by 17
Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy
Yang, M., Zhong, P., & Wei, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052056 · Cited by 17
Conserved genetic basis for microbial colonization of the gut
Liu, M., Blattman, S. B., Takahashi, M., Nandan, M. O., Jiang, W., Oikonomou, P., Tavazoie, S. F., & Tavazoie, S. (2025) · Cell · doi:10.1016/j.cell.2025.03.010 · Cited by 16
Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy
Zheng, J., & Chen, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429722 · Cited by 19
Engineered bacteria potentiate cancer immunotherapy
Sun, M., Yang, J.-Z., Li, L., Li, Y., Li, W., & Ding, J. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111093 · Cited by 17
Engineered bacterial therapeutics for detecting and treating CRC
Siguenza, N., Brevi, A., Zhang, J. T., Pabani, A., Bhushan, A., Das, M., Ding, Y., Hasty, J., Ghosh, P., & Zarrinpar, A. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.04.001 · Cited by 16
A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments
Gulig, P. A., Swindle, S., Fields, M. A., & Eisenman, D. (2024) · Applied Biosafety · doi:10.1089/apb.2024.0002 · Cited by 19
Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives
Liu, J., He, C., Tan, W., & Zheng, J. H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122897 · Cited by 14
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 18
Targeting the Tumor Microbiota in Cancer Therapy Basing on Nanomaterials
Niu, Y., Feng, J., Ma, J., Xiao, T., & Yuan, W. (2025) · Exploration · doi:10.1002/exp.20210185 · Cited by 20
Recent Advances in Spatiotemporal Manipulation of Engineered Bacteria for Precision Cancer Therapy
Chang, X., Liu, X., Wang, X., Ma, L., Liang, J., & Li, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s516523 · Cited by 14
Colorectal cancer: the immune microenvironment and the gut microbiota – new perspectives, challenges, and opportunities
Zhou, P., Zhang, W., Liao, Y., Zhai, Z., Lu, S., Jiang, S., Hu, W., & Gong, W. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002573 · Cited by 17
An Engineered Probiotic Consortium Based on Quorum‐Sensing for Colorectal Cancer Immunotherapy
Guo, Y., Gao, M., Wang, L., Yuan, H., Yin, J., Wu, J., Gao, X., Zhu, Z., Zhang, Y., Wang, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202512744 · Cited by 14
Recent advances of engineered bacteria for therapeutic applications
Xiang, X., Zhou, Z., Rao, X., & Jiang, X. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.013 · Cited by 17
Nanoparticle/Engineered Bacteria Based Triple-Strategy Delivery System for Enhanced Hepatocellular Carcinoma Cancer Therapy
Yang, M., Chen, W., Gupta, D., Mei, C., Yang, Y., Zhao, B., Qiu, L., & Chen, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s453709 · Cited by 14
An Explainable Graph Neural Framework to Identify Cancer‐Associated Intratumoral Microbial Communities
Liu, Z., Sun, Y., Li, Y., Ma, A., Willaims, N. F., Jahanbahkshi, S., Hoyd, R., Wang, X., Zhang, S., Zhu, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202403393 · Cited by 15
Chemical genetic approaches to dissect microbiota mechanisms in health and disease
Yang, X., & Hang, H. C. (2024) · Science · doi:10.1126/science.ado8548 · Cited by 16
Advancing cell therapies with artificial intelligence and synthetic biology
Choudhury, M., Deans, A. J., Candland, D. R., & Deans, T. L. (2025) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2025.100580 · Cited by 14
Strategies for engineering biomimetic materials for tumor therapy
Ma, Z., Zhang, K., & Zhao, Y. (2025) · Matter · doi:10.1016/j.matt.2024.10.017 · Cited by 13
Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial
Yang, Y. P., Guo, Y., Ding, Y., Li, J., Liang, L., Shi, D., Li, X., & Ma, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102234 · Cited by 14
Hitchhiking Delivery Systems: Therapeutic Hydrogels as Advanced Tools for Immunomodulatory Applications
Zhao, Y., Song, S., Zhang, J., Ren, X., & Zhao, Y. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00923 · Cited by 17
Micro-nano microbial fuel cell-driven bioelectrochemical tumor therapy
Li, R., Kang, Y., Ran, N., Niu, G., Fan, Y., Zhang, Y., Ye, J., Xue, Y., Shi, J., Ding, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64023-8 · Cited by 14
Engineered Bacteria-Nano Hybrid System: The Intelligent Drug Factory for Next-Generation Cancer Immunotherapy
Zi, G., Zhou, W., Zhou, L., Wang, L., Zheng, P., & Wei, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101349 · Cited by 16
Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy
Zhang, Z., Cui, D., Wang, H., Wu, L., & Liu, X. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04278-8 · Cited by 13
Advances of Bacterial Biomaterials for Disease Therapy
Lin, Z., Fu, L., Wei, W., & Zheng, D. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00022 · Cited by 13
Engineering bacterial theranostics: from logic gates to in vivo applications
Armstrong, A., & Isalan, M. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1437301 · Cited by 13
Progress and challenges of functionalized bacterial encapsulation: A novel biotechnology for next-generation biotherapeutics
Zhang, Y., Wu, Y., Zhao, X., Ye, Q., Cao, L., Liu, M., Gao, B., Niu, Q., Chen, N., Duan, Z., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.028 · Cited by 12
Living drugs: A wonderful evolution for therapeutic applications
Chintalapati, S. S. V. V., Sang, N., Miyahara, M., Iwata, S., Nishida, K., & Miyako, E. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100193 · Cited by 13
Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine
Zhao, L., Xin, J., Hu, M., Xue, C., & Dong, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.028 · Cited by 15
In Vivo CAR-T Therapies—A New Era of Programmable Immunity
Pierini, S., Qureshi, R., Pustylnikov, S., Bartosh, Z., & Akimova, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041737 · Cited by 13
CAR-T cell therapy: Advances in digestive system malignant tumors
Xu, N., Wu, Z., Pan, J., Xu, X. L., & Wei, Q. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200872 · Cited by 12
Probiotics prevent pegylated liposomal doxorubicin-associated hand-foot syndrome and oral mucositis of breast cancer patients following surgery and chemotherapy: a randomized placebo-controlled trial
Juan, Z., Chen, J., Ding, B., Yongping, L., Cai, H., Chen, H., Wang, L., Le, Y., Shi, J., Wu, Y., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002147 · Cited by 13
Cell Surface‐Tethered Nucleic Acid Therapeutics Program Robust and Tumor‐Responsive Enhancement of Adoptive Cell Therapy
Gao, M., Liu, Y., Zhao, L., Chen, J., Wan, W., Yuan, Z., Li, L., Huang, Y., Wang, Y., & Zheng, Y. (2025) · Advanced Materials · doi:10.1002/adma.202419969 · Cited by 15
Probiotic-mediated tumor microenvironment reprogramming with protease-sensitive interleukin-15 and photothermal therapy
Wang, H., Zheng, L., Yang, C., Lin, J. H., Zhou, R., Liu, H., Dong, Y., Xu, X., Shi, G., Yang, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102191 · Cited by 12
Engineered bacteria guide T cells to tumors
Bressler, E. M., & Wong, W. W. (2023) · Science · doi:10.1126/science.adk6098 · Cited by 12
Pathophysiology of colitis-associated colorectal cancer
Neufert, C. F., & Neurath, M. F. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01197-6 · Cited by 13
Advancements in the impact of human microbiota and probiotics on leukemia
Zhang, Y., Zhao, X., Zhang, J., Zhang, Y., & Wei, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1423838 · Cited by 11
The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives
Zhou, L., Duan, Y., Fu, K., Zhang, M., Li, K., & Yin, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1426050 · Cited by 11
CAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions
Li, W., Huang, Y., Zhou, X., Cheng, B., Wang, H., & Wang, Y. (2024) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2024e13640 · Cited by 14
Genetically Engineered Bacteria as A Living Bioreactor for Monitoring and Elevating Hypoxia‐Activated Prodrug Tumor Therapy
Zhang, H., Chen, L., Chen, Q., Chen, Q., & Zhou, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402272 · Cited by 11

Authors: Vincent, R. L., Gurbatri, C. R., Li, F., Vardoshvili, A., Coker, C., Im, J., Ballister, E. R., Rouanne, M., Savage, T., de los Santos-Alexis, K., Redenti, A., Brockmann, L., Komaranchath, M., Arpaia, N., & Danino, T.
Affiliations: Columbia University (US)
Herbert Irving Comprehensive Cancer Center (US)
Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Corresponding author: Vincent, Rosa L.
Gurbatri, Candice R.
Danino, Tal
ORCID: Vincent, Rosa L.
Gurbatri, Candice R.
Li, Fangda
Coker, Courtney
Im, Jongwon
Ballister, Edward R.
Rouanne, Mathieu
Savage, Thomas
de los Santos-Alexis, Kenia
Redenti, Andrew
Brockmann, Leonie
Komaranchath, Meghna
Arpaia, Nicholas
Danino, Tal
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2023-10-13
Volume: 382
Issue: 6667
Pages: 211-218
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.add7034
PMC: PMC10915968
OpenAlex: W4387568373
Cited by: 273
References: 65
Citations by year: 2026: 88 · 2025: 114 · 2024: 65 · 2023: 6
FWCI: 35.37
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Science Foundation (P30CA013696, 1644869)
University of Washington
National Institutes of Health (UL1TR001873, 1644869)
National Cancer Institute (P30CA013696)
National Institute of Biomedical Imaging and Bioengineering (R01EB030352)
National Center for Advancing Translational Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: chimeric antigen receptor T cells, solid tumors, tumor heterogeneity, cancer immunotherapy
MeSH terms: Receptors, Chimeric Antigen, Animals, Antigens, Neoplasm, Breast Neoplasms, Escherichia coli, Humans, Lymphocyte Activation, T-Lymphocytes, Colorectal Neoplasms, Immunotherapy, Adoptive, Probiotics, Xenograft Model Antitumor Assays, Mice, Cell Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Probiotic-guided CAR-T cells for solid tumor targeting

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks